O-GlcNAcylation of progranulin promotes hepatocellular carcinoma proliferation

被引:0
作者
Liang, Yi [1 ]
Chen, Liqiong [1 ,2 ]
Huang, Zhuanglin [1 ]
Li, Yueliang [1 ]
Weng, Hanqin [3 ]
Guo, Lianxian [1 ]
机构
[1] Guangdong Med Univ, Dongguan Affiliated Hosp 1, Inst Lab Med, Sch Med Technol,Guangdong Prov Key Lab Med Mol Dia, Dongguan 523000, Peoples R China
[2] Zhanjiang Cent Peoples Hosp, Dept Clin Lab, Zhanjiang, Peoples R China
[3] Dongguan Peoples Hosp, Dept Gen Surg, Dongguan 523000, Peoples R China
关键词
PGRN; O-GlcNAcylation; Hepatocellular carcinoma; Proliferation;
D O I
10.1016/j.bbrc.2024.151150
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Progranulin (PGRN) is overexpressed and implicated in hepatocellular carcinoma (HCC) development; however, its post-translational modifications and regulatory mechanisms in HCC remain largely unexplored. Here, the expression levels of PGRN, OGT, and O-GlcNAcylation were found to be elevated in both HCC samples and cell lines. LC-MS/MS analysis and immunoprecipitation revealed that PGRN underwent O-linked N-acetylglucosamine (O-GlcNAc) modification at threonine 272 (Thr272). Co-immunoprecipitation and confocal microscopy confirmed the interaction and colocalization of O-GlcNAc transferase (OGT) with PGRN. Reducing O-GlcNAcylation increased the ubiquitination of PGRN, while increasing O-GlcNAcylation inhibited ubiquitination and elevated PGRN stability, as measured by cycloheximide (CHX) chase experiments. This regulation of PGRN stability was directly linked to its expression levels. Moreover, mutation at the primary O-GlcNAc site Thr272 inhibited the activity of the PI3K/AKT/mTOR signaling pathway and suppressed HCC cell proliferation. Together, our findings indicate that O-GlcNAcylation at Thr272 is essential for PGRN-driven HCC cell proliferation.
引用
收藏
页数:8
相关论文
共 28 条
[1]  
Chaiyawat P, 2016, CANCER GENOM PROTEOM, V13, P387
[2]  
Chatham J.C., 2020, Role of O-Linked N-Acetylglucosamine (OGlcNAc) Protein Modification in Cellular (Patho)physiology
[3]  
Cheung PFY, 2018, METHODS MOL BIOL, V1806, P145, DOI 10.1007/978-1-4939-8559-3_11
[4]   Characterization of a mouse monoclonal antibody specific for O-linked N-acetylglucosamine [J].
Comer, FI ;
Vosseller, K ;
Wells, L ;
Accavitti, MA ;
Hart, GW .
ANALYTICAL BIOCHEMISTRY, 2001, 293 (02) :169-177
[5]   Progranulin: A conductor of receptors orchestra, a chaperone of lysosomal enzymes and a therapeutic target for multiple diseases [J].
Cui, Yazhou ;
Hettinghouse, Aubryanna ;
Liu, Chuan-ju .
CYTOKINE & GROWTH FACTOR REVIEWS, 2019, 45 :53-64
[6]   A GRN Autocrine-Dependent FAM135B/AKT/mTOR Feedforward Loop Promotes Esophageal Squamous Cell Carcinoma Progression [J].
Dong, Dezuo ;
Zhang, Weimin ;
Xiao, Wenchang ;
Wu, Qingnan ;
Cao, Yiren ;
Gao, Xiaohan ;
Huang, Lijie ;
Wang, Yan ;
Chen, Jie ;
Wang, Weihu ;
Zhan, Qimin .
CANCER RESEARCH, 2021, 81 (04) :910-922
[7]   Regulation of lysosomal trafficking of progranulin by sortilin and prosaposin [J].
Du, Huan ;
Zhou, Xiaolai ;
Feng, Tuancheng ;
Hu, Fenghua .
BRAIN COMMUNICATIONS, 2022, 4 (01)
[8]   Anti-progranulin/GP88 antibody AG01 inhibits triple negative breast cancer cell proliferation and migration [J].
Guha, Rupa ;
Yue, Binbin ;
Dong, Jianping ;
Banerjee, Aditi ;
Serrero, Ginette .
BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (03) :637-653
[9]   O-GlcNAcylation in cancer development and immunotherapy* [J].
He, Xue-Fen ;
Hu, Xiaoli ;
Wen, Gao-Jing ;
Wang, Zhiwei ;
Lin, Wen-Jing .
CANCER LETTERS, 2023, 566
[10]   Progranulinopathy: A diverse realm of disorders linked to progranulin imbalances [J].
Huang, Guiwu ;
Jian, Jinlong ;
Liu, Chuan-Ju .
CYTOKINE & GROWTH FACTOR REVIEWS, 2024, 76 :142-159